Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EBS vs EHTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EBS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

EBS Overall Winner 6-Pillar Tally: EBS 4 – 2 EHTH Matrix Metrics: EBS 5 – 5 EHTH

As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EBS carries a Unified Composite Score of 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin), whereas EHTH carries 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin).

  • Technical & Structure Timing Caution: EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8); meanwhile EHTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EBS vs EHTH
EBS NYSE Head-to-Head Winner
Emergent Biosolutions, Inc.
Pharmaceutical Preparations
$5.63
-3.1% 1D
Market Cap $297.7M
TTM Revenue $649M
Forward P/E 20.0x
Beta / 30D Vol 0.81β · 49% Vol
Unified Composite Score
54.3 / 100 HOLD
Tech 58.0 Fund 55.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.8 · SMA20: $6.24 · SMA50: $6.49
EHTH NASDAQ
eHealth, Inc.
Insurance Agents, Brokers & Service
$0.35
-9.36% 1D
Market Cap $13.4M
TTM Revenue $469M
Forward P/E 0.2x
Beta / 30D Vol 1.61β · 117% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 25
RSI-14: 24.9 · SMA20: $0.50 · SMA50: $0.65

6-Pillar Scorecard Institutional Category Breakdown (EBS 4 – 2 EHTH)

Columns: Metric · EBS · EHTH
1. Valuation Multiples EHTH
Forward P/E 20.0x 0.2x
Trailing P/E 20.0x 0.2x
PEG Ratio 0.38x 0.72x
EV / Revenue 1.0x N/M
2. Growth & Scale EBS
Revenue Growth (YoY) -52.4% -60.5%
Earnings Growth (YoY) -93.8% -17.6%
TTM Revenue (USD) $649M $469M
Market Cap $297.7M $13.4M
3. Profitability & Quality EHTH
Gross Margin 43.4% 100.0%
Operating Margin 5.8% 11.9%
Net Profit Margin -40.2% 4.9%
Return on Equity (ROE) -58.2% 2.6%
4. Balance Sheet & Cash Flow EBS
Cash Generation (TTM) $188M $58M EBITDA
Cash Flow Margin 29.0% 12.4% EBITDA Mgn
Net Cash / Leverage $332M Net Debt (1.62x D/E) $15.36 Book/Sh · 2.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EBS
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 73.2% (4th %ile) 128.7% (56th %ile)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EBS
OpEx & R&D Intensity 37.6% of Rev ($244M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Insurance Brokers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EBS (5) vs EHTH (5)
Institutional Metric EBS EHTH Criterion Row Edge
Market Capitalization
Scale
$297.7M $13.4M Larger Scale EBS
Trailing P/E Ratio
Valuation
20.0x 0.2x Lower Multiple EHTH
Forward P/E Ratio
Valuation
20.0x 0.2x Lower Multiple EHTH
Revenue Growth (YoY)
Growth
-52.4% -60.5% Higher Growth EBS
Operating Margin (TTM)
Profitability
5.8% 11.9% Higher Margin EHTH
Net Profit Margin
Profitability
-40.2% 4.9% Higher Margin EHTH
Return on Equity (ROE)
Capital Efficiency
-58.2% 2.6% Higher ROE EHTH
52-Week Range Position
Momentum
13% ($4–$14) 0% ($0–$5) Stronger Trend EBS
Beta / 30D Volatility
Risk Regime
0.81β · 49% Vol 1.61β · 117% Vol Lower Realized Risk EBS
Unified Institutional Score
Composite Signal
54.3 / 100 (HOLD) 40.8 / 100 (SELL) Higher Composite EBS
Trailing 12M Revenue (USD)
Operating Scale
$649M $469M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
43.4% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 1.0x EV/Rev 0.72x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$188M ($332M Net Debt (1.62x D/E)) $58M EBITDA ($15.36 Book/Sh · 2.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EBS +27.15 pp
EBS: -11.48% · EHTH: -38.63%
3M Horizon EBS +87.16 pp
EBS: +15.13% · EHTH: -72.03%
6M Horizon EBS +50.15 pp
EBS: -30.15% · EHTH: -80.3%
1Y Horizon EBS +46.61 pp
EBS: -44.31% · EHTH: -90.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EBS vs EHTH. Trailing 12-month operating profitability (EBS 5.8% vs EHTH 11.9%) and valuation multiples (EBS 20.0x vs EHTH 0.2x Forward P/E) are benchmarked directly in Pillar 4 below.

EBS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$649M
Gross Margin43.4%
Op. Margin5.8%
ROE / Fwd P/E-58.2% · 20.0x
EHTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$469M
Gross Margin100.0%
Op. Margin11.9%
ROE / Fwd P/E2.6% · 0.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EBS CONSOLIDATION
31d in phase · OBV DISTRIBUTION
Current IV 73.2%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EBS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EHTH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 128.7%
IV Percentile 56th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EHTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $5.81 · IV 78.8%

EBS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($581)

Compare $581 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 78.8% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $6 / $7 Bull Call Spread

Buy 4x $6C · Sell 4x $7C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$21 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $5P / $6-$7C Seagull

Sell 2x $5P · Buy 2x $6/$7C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$27 (+14.0% RoM)
Max Risk / Buffer -13.9% Put Cushion ($190 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EBS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $297.7M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($244M)
90D Engineering Disclosures 0 Published
EHTH Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $13.4M market capitalization and 11.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EBS vs EHTH Key Questions & Quantitative Answers

As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EBS carries a Unified Composite Score of 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin), whereas EHTH carries 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin). Technical & Structure Timing Caution: EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8); meanwhile EHTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EBS leads the Growth & Scale pillar: EBS posts -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin), compared with EHTH at -60.5% YoY revenue growth and -17.6% YoY earnings growth on $469M TTM revenue (100.0% gross margin, 11.9% operating margin). On trailing 12-month operating scale, EBS generates $649M in USD-normalized revenue versus $469M for EHTH. In operating R&D and SG&A reinvestment, EBS deploys 37.6% of Rev ($244M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EHTH.

EHTH screens cheaper on headline valuation multiples. EBS trades at 20.0x Forward P/E, 20.0x Trailing P/E, 0.38x PEG, and 1.0x EV/Revenue (29.0% FCF margin), whereas EHTH trades at 0.2x Forward P/E, 0.2x Trailing P/E, 0.72x PEG, and N/M EV/Revenue (12.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EBS (-58.2% ROE) versus EHTH (2.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EBS carries 73.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.81β · 49% Vol realized risk). By comparison, EHTH carries 128.7% implied volatility (56th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.